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ORIGINAL ARTICLE
Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center
Urban Experience, Detroit, MI, USA
Nino Balanchivadzea, Adam A. Kudirkab, Sally Askarb, Khaled Almadhounb, Philip Kuriakosea, Raef Fadelb and
Vrushali Dabaka
aDepartment of Hematology and Oncology, Henry Ford Health System, Detroit, MI, USA; bDepartment of Internal Medicine, Henry Ford
Health System, Detroit, MI, USA
ABSTRACT
The city of Detroit has a large population of individuals with sickle cell disease, and hospitals in Detroit
have seen some of the highest numbers of cases of coronavirus disease-19 (COVID-19) in 2020. The
purpose of this study was to examine the pathophysiological characteristics of COVID-19 in patients
with sickle cell disease or trait to determine whether these patients have unique manifestations that
might require special consideration. This retrospective analysis included 24 patients with confirmed
COVID-19 and sickle cell disease or trait who were seen at the Henry Ford Hospital, Detroit, MI, USA,
between March 1 and April 15 2020. Of the 24 patients, 18 (75.0%) had heterozygous sickle cell trait,
one (4.0%) was a double heterozygote for Hb S (HBB: c.20A>T)/bþ-thalassemia (bþ-thal), four had sickle
cell anemia (bS/bS) and one (4.0%) had Hb S/Hb C (HBB: c.19G>A) disease. A total of 13 (54.0%)
patients required hospitalization. All four patients with sickle cell anemia, developed acute pain crisis.
We observed one patient who developed acute pulmonary embolism and no patients developed other
sickle cell associated complications. Additionally, three (13.0%) patients required packed red blood cell
transfusion without the need of exchange transfusion, and one patient required admission to the
intensive care unit (ICU), mechanical ventilation and subsequently died. Patients with sickle cell disease
or trait and laboratory-confirmed COVID-19 had a generally mild, or unremarkable, course of disease,
with lower chances of intubation, ICU admission and death, but with a slightly longer hospitalization.
ARTICLE HISTORY
Received 3 June 2020
Revised 7 July 2020
Accepted 8 July 2020
KEYWORDS
Coronavirus disease-19
(COVID-19); sickle cell
disease; sickle cell trait;
severe acute respiratory
syndrome coronavirus 2
(SARS-CoV-2); acute
respiratory distress
syndrome (ARDS)
Introduction
In December 2019, the first cases of respiratory disease
attributable to a novel enveloped RNA b coronavirus, now
known as severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), were identified in Wuhan, People’s Republic
of China [1]. The disease, referred to as COVID-19, has
now spread to every continent, with the exception of
Antarctica. According to the World Health Organization, at
the time of writing this report, there were more than 5 mil-
lion confirmed cases with over 350,000 deaths [2].
Patients infected with SARS-CoV-2 experience a broad
spectrum of symptoms, with approximately 80.0% of
infected patients being classified as mild, 15.0% of cases as
severe (dyspnea, hypoxia, or >50.0% of lung involvement on
imaging) and 5.0% percent of patients being classified as
critical (respiratory failure requiring intubation or shock)
[3]. Between 20.0 and 40.0% of patients with severe disease
develop acute respiratory distress syndrome (ARDS) [4,5].
According to a recent retrospective analysis of 5700
patients hospitalized in New York City, the three most com-
mon comorbidities with COVID-19 were hypertension, obe-
sity and diabetes. Those who required mechanical
ventilation had the highest mortality rate [6]. Older age,
high sequential organ failure assessment (SOFA) score, and
D-dimer greater than 1.0 mg/mL were associated with poor
prognosis at an early stage in a retrospective multicenter
cohort study from China [7].
Sickle cell disease is a general term that describes an
inherited group of disorders characterized by the presence of
abnormal hemoglobin (Hb), Hb S (HBB: c.20A>T), caused
by a point mutation at codon 6 of the b-globin gene. Hb S
becomes poorly soluble when deoxygenated [8], causing red
blood cells (RBCs) to distort into a crescent or sickle cell
shape. Inciting events such as infection may cause hypoxia,
which may lead to a sickle cell crisis resulting in vascular
occlusion and major organ complications. This predisposi-
tion to major organ complications and susceptibility to hyp-
oxia in patients with sickle cell disease was cited as one of
the most frequent comorbidities seen in hospitalized patients
during the H1N1 pandemic [9]. Note that sickle cell disease
encompasses multiple genotypes, including a specific genetic
profile called sickle trait. Collectively, the term sickle cell
disease or trait (sickle cell disease/sickle cell trait) encom-
passes all individuals with at least one copy of the sickle cell
disease Hb S gene.
While the mechanisms leading to ARDS in COVID-19
need to be investigated, we wanted to study the effect of
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SARS-CoV-2 on patients who have sickle cell disease/sickle
cell trait due to these patients’ unique Hb phenotype and
the prevalence of hypoxia as a hallmark of COVID-19.
Importantly, individuals with sickle cell disease/sickle cell
trait may or may not be manifesting anemia- or sickle cell-
related symptoms, and our study sought to investigate the
sickle cell disease/sickle cell trait process within the context
of COVID-19. Many case series of COVID-19 infected hos-
pitalized patients have been published so far, but studies of
patients with sickle cell disease/sickle cell trait are sparse.
Here we present a retrospective analysis of all patients
with sickle cell disease/sickle cell trait who presented at the
Henry Ford Health System, Detroit, MI, USA, from 1 March
to 15 April 2020. We examined these patients’ hospital
course, laboratory findings, need for hospitalization, inten-
sive care unit (ICU) admission, packed RBC (PRBC) trans-
fusion, and mortality.
Methods
This was a retrospective case study of data from adult
patients with laboratory-confirmed COVID-19 and sickle
cell disease/sickle cell trait who were evaluated at the Henry
Ford Health System between March 1 and April 15 2020.
The diagnosis of COVID-19 was made based on typical clin-
ical and radiographic findings and a positive SARS-CoV-2
reverse-transcription polymerase chain reaction (RT-PCR)
test from nasopharyngeal swab specimens performed at the
Henry Ford Hospital. Sickle cell disease/sickle cell trait and
comorbidities were determined based on patients’ report and
chart documentation on admission. Not all patients had Hb
electrophoresis available for confirmation. All cases that met
our inclusion criteria were analyzed. Data were reviewed by
all authors.
Sickle cell trait is the term used to refer to sickle cell dis-
ease patients who are heterozygous for Hb S, while patients
who are homozygous are referred to as having sickle cell
anemia (bS/bS). Additionally, patients with one copy of the
Hb S gene and one copy of the Hb C (HBB: c.19G>A) gene
are referred to as having Hb S/Hb C, and patients who are
heterozygous for two blood disorders have Hb S/
bþ-thalassemia (Hb S/bþ-thal). All four genotypes were rep-
resented in our study group and are collectively referred to
as sickle cell disease/sickle cell trait patients.
The primary endpoint of our study was a composite mea-
sure that consisted of the admission to the hospital, admis-
sion to intensive care unit (ICU), duration of
hospitalization, requirement of supplemental oxygen (by any
means) or invasive ventilation, requirement of blood transfu-
sion (simple or exchange), and death. The secondary end-
point was the mortality rate.
Inclusion criteria included all adult patients with a previ-
ous diagnosis of sickle cell disease/sickle cell trait with con-
firmed SARS-CoV-2 RNA RT-PCR testing. We excluded
patients with suspected but not confirmed COVID-19 or
hospitalization at an outside hospital for their initial diagno-
sis. The study protocol was approved by the Henry Ford
Institutional Review Board.
Results
Between March 1 and April 15 2020, 40 patients sickle cell
disease/sickle cell trait suspected to have COVID-19, were
evaluated at Henry Ford Health System. A total of 24
patients with laboratory-confirmed COVID-19 who met our
criteria were included (Table 1) in this study. The mean age
of our study group was 52.9 years (range: 24–87 years). Of
our patients, 18 (75.0%) were women, six (25.0%) were men,
22 (92.0%) were African American, and 13 (54.0%) required
hospital admission.
The most common presenting symptom was a cough (20
patients, 83.0%), followed by fever (19 patients, 79.0%).
Table 1. Demographics and medical comorbidities of the studied patients.
Demographics Patients (n¼ 24) %
Ethnicity:
African American 22 92.0
not African American 2 8.0
Age (years):
>60 9 38.0
<60 15 63.0
Gender:
Men 6 25.0
Women 18 75.0
Sickle cell disease types:
Hb S (HBB: c.20A>T) 4 17.0
Hb S/Hb C (HBB: c.19G>A) 1 4.0
sickle cell trait 18 75.0
Hb S/b-thal trait 1 4.0
Comorbidities:
COPD 1 4.0
Asthma 3 13.0
HIV positive 0 0.0
Hypertension 12 50.0
Diabetes 9 38.0
BMI >30 12 50.0
End-stage renal disease 3 13.0
History of malignancies 5 21.0
History of VTE 6 25.0
COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency
virus; BMI: body mass index; VTE: venous thromboembolism.
Table 2. Presenting symptoms and triage vital signs.
Triage Vital Signs n (%) Total Tested (n)
Temperature >38.0 C 10 (40.0) 24
Temperature (median C) 37.0 (36.4-39.9) 24
Oxygen saturation:
<90.0% on room air 3 (12.0) 24
median saturation on room air 94.0 24
Received supplemental oxygen 7 (28.0) 24
Respiratory rate >24/min. 2 (8.0) 24
Heart rate:
>100 beats/min. 9 (36.0) 24
Median 94 beats/min. 24
Presenting symptoms:
Fever 19 (79.0)
Chills 14 (58.0)
Headache 7 (29.0)
Myalgia 16 (67.0)
Change in taste 3 (13.0)
Change in smell 2 (8.0)
Shortness of breath 15 (63.0)
Cough 20 (83.0)
Nausea 5 (21.0)
Vomiting 4 (17.0)
Anorexia 7 (29.0)
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Shortness of breath and myalgia were reported in 15 (63.0%)
and 16 (57.0%) patients, respectively. Loss of taste or smell
and gastrointestinal and neurologic complaints were less
common (Table 2). Duration of symptoms varied with a
mean of 7 days (range 1–28 days). All hospitalized patients
were treated with hydroxychloroquine and/or systemic ste-
roids in addition to supportive measures. A total of seven
patients (29%) required supplemental oxygen administration,
and only one patient (4.0%) required intubation and ICU
admission (Table 3).
Of the 24 cases, 18 (75.0%) patients had heterozygous
sickle cell trait, four (17.0%) patients had sickle cell anemia
(bS/bS), one (4.0%) patient was a double heterozygote for
Hb S/b-thal, and one (4.0%) had Hb S/Hb C disease (Table
1). Only two (8.0%) patients were taking folic acid supple-
mentation as outpatients, while no patients reported taking
hydroxyurea (HU).
Of the 24 patients, 15 (63.0%) reported having at least
one comorbidity, while 12 patients (50.0%) reported hyper-
tension, 12 (50.0%) had a body mass index (BMI) of >30.
Only one patient was receiving immunosuppressive medica-
tions due to renal transplant. No patients had a reported
history of chronic respiratory failure requiring oxygen sup-
plementation at home, and six patients (25.0%) had a history
of venous thromboembolism (VTE). All tested patients were
negative for human immunodeficiency syndrome and were
negative for influenza H1N1. There were two patients
(8.0%), who had reported non metastatic solid malignancies,
but were not receiving active chemotherapy (Table 1).
Notable laboratory findings included absolute lymphocyte
count (ALC) <1.0 109/mL in 40.0% of cases. The mean
presenting ferritin level was found to be 820.14 ng/dL, with
>1000.0 ng/dL found in 40.0% of patients tested during hos-
pitalization. Average presenting D-dimer was reported as
3.59mg/mL with >10mg/mL in 23.1% patients tested during
hospitalization. Serum troponin was elevated in 26.7% of
patients at initial triage. Only one patient had a Hb level of
<7.0 g/dL, and 20.0% of patients tested had Hb levels of
<10.0 g/dL during their hospital stay (Tables 4 and 5).
All sickle cell anemia patients required hospitalization
and developed acute sickle cell pain crisis. Of the 18 patients
with sickle cell trait, 11 (61%) were hospitalized. Only one
of the 18 patients with sickle cell trait (5.5%) required ICU
admission, intubation and mechanical ventilation, and subse-
quently died. This patient had been on chronic immunosup-
pressive therapy due to history of a failed renal transplant,
had extensive cardiac disease, and was requiring intermittent
renal replacement therapy. Average length of stay of hospi-
talization for patients with sickle cell trait was 7.6 days
(range 2–21 days), while the average length of stay of
patients with sickle cell anemia was 4.75 days (range
2–8 days). Of the three patients that required PRBC transfu-
sions, only one hospitalized patient had sickle cell trait and
required >5 units PRBC transfusions (Table 3). None of the
patients developed acute chest syndrome (ACS) or needed
exchange transfusions. A single patient that was a double
heterozygote for Hb S/b-thal trait developed pulmonary
embolism but did not require invasive ventilation or ICU
admission and was discharged home without supplemen-
tal oxygen.
Discussion
In this retrospective case analysis, we describe the impact of
COVID-19 on patients with sickle cell disease/sickle cell
trait, who had presented to our institution. Overall, we
found that the effect of COVID-19 on this patient popula-
tion was mild, such that we did not observe any unusually
severe outcomes compared to a general course of the infec-
tion. Surprisingly, despite a large population of patients with
sickle cell disease/sickle cell trait in Detroit, the proportion
of patients with sickle cell disease/sickle cell trait and labora-
tory confirmed COVID-19 infection that presented to the
emergency department to seek care during our study period
was, in our view, quite small. A total of 4688 patients with a
diagnosis of COVID-19 were seen at the Henry Ford Health
System from March 1 and April 15 2020, and patients with
sickle cell disease/sickle cell trait represented only 0.5% of
the total patient population. Considering that hypoxia is a
troubling complication of COVID-19, we note that one
sickle cell disease/sickle cell trait patient required ICU
admission, mechanical ventilation, and subsequently died of
multi organ failure. This patient also had multiple comor-
bidities, including chronic immuno-suppressed state due to
prior renal transplant, worsening chronic renal disease
requiring intermittent hemodialysis, and a history of cardiac
disease. None of the patients developed ACS or any other
complications to warrant exchange transfusions.
A recent large case series of all sequentially hospitalized
patients with confirmed COVID-19 demonstrated that
14.2% required ICU care, 12.2% received invasive mechani-
cal ventilation, and 21.0% died, and overall length of stay
was 4.1 days [6]. Our findings within a specific sickle cell
disease/sickle cell trait population showed a lower percentage
of patients requiring ICU admission, fewer mechanical ven-
tilations and a lower rate of mortality. The hospital length of
stay was longer in our cohort, which can be explained in
part by the presence of one critically ill patient who had a
21-day hospitalization.
We think the low number and unremarkable course of
the COVID-19 infection on our patient population could be
explained by several interventions. First, the overall number
of COVID-19 affected patients with sickle cell disease/sickle
cell trait could be lower due to social distancing that was
put in effect early in the pandemic in the State of Michigan.
Second, at the Henry Ford Hospital, we have a specialized
Sickle Cell Disease Clinic with well-established guidance for
our patients, including prompt outpatient management of
painful crises, infusion room-based intravenous hydration,
pain control, and outpatient management of mild viral ill-
nesses. It is possible that some of the patients had been
using outpatient resources rather than presenting to the hos-
pital for evaluation and therefore did not get tested for
COVID-19 due to presentation of acute painful crisis, which
could mimic COVID-19 presentation. In a similar fashion,
we do not know how many patients that presented to our
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hospital with acute pain crises did not get tested for
COVID-19. Additionally, those patients who were admitted
to the hospital were treated early and aggressively, as our
hospital had the unfortunate advantage of being one of the
national ‘hot-spots’ for COVID-19. This resulted in rapid,
effective training of staff and implementation of structured
protocols for care of patients with COVID-19.
Lastly, we wonder if chronic sickle cell disease therapy
might have a protective effects on the sickle cell disease/
sickle cell trait patient population. In our cohort, we did not
have any patients with sickle cell disease taking HU. It is
possible that those patients who have sickle cell anemia and
are compliant with HU did not develop symptomatic disease
needing emergency room evaluation and admission.
Most of our patients had sickle cell trait, which could
have been a contributing factor to the relatively mild course
of disease we observed. A potential mechanism explaining
this phenomenon may be hinted at in a previous study [10],
Table 3. Clinical measures and outcomes for the studied patients.
Outcome Measures (n¼ 24) n (%) with Outcome Total Patients
Hospitalizations 13 (54.0) 24
Sickle cell trait hospitalizations 11 (61.0) 18
Hb S, Hb S/Hb C, Hb S/b-thal hospitalizations 4 (100.0) 4
ICU admissions 1 (4.0%) 24
ICU admissions (het. sickle cell trait) 1 (5.5%) 18
Oxygen supplementation 5 (21.0) 24
Intubation/mechanical ventilation (het. sickle cell trait) 1 (5.5) 18
Sickle cell acute pain crisis 4 (17.0) 24
Sickle cell acute pain crisis (het. sickle cell trait) 0 (0.0) 18
PRBC transfusions 3 (13.0) 24
PRBC transfusions (het. sickle cell trait) 1 (5.5) 18
30-day readmissiona 2 (15.4) 13
Death 1 (4.0) 24
Death (het. sickle cell trait) 1 (5.5) 18
ICU: intensive care unit; het.: heterozygous; PRBC: packed red blood cell transfusions.
aReadmission rates were calculated for patients who were initially admitted.
Table 4. Presentation of laboratory results of patients diagnosed with COVID-19 (n¼ 24).
Parameters Assay Mean (range) or % Patients (n) Patients Tested (n) Reference Ranges
Admission Laboratory Values
WBC (109/L) 9.03 (2.50–27.8) 20 3.80.10.6
ALC (109/L) 1.45 (0.10–6.32) 20 1.10–4.00
ALC <1.0, % (n) 40.0 (4) 20
Plateles (109/L) 248.25 (39.00–450.00) 20 150.00–450.00
Platelets <150.00, % (n) 15.00 (3) 20
AST (IU/L) 65.33 (14.00–276.00) 15 <35.00
ALT (IU/L) 37.40 (12.00–101.00) 15 <52.00
CPK (IU/L), total 218.50 (22.00–1048.00) 14 <250.00
CPK (IU/L), total, (maximum)a 272.71 (22.00–1048.00) 14 <250.00
Ferritin (ng/dL) 820.14 (63.00–2038.00) 15 24.00–336.00
Ferritin (ng/dL) (maximum) 1312.32 (88.00–5218.00) 15 24.00–336.00
Ferritin <1000.00 ng/dL, % (n) 40.0 (6) 15
CRP (mg/dL) 7.40 (0.40–19.70) 14 <0.50
CRP (mg/dL) (maximum) 10.40 (0.50–43.00) 15 <0.50
LDH (IU/L) total 381.73 (173.00–742.00) 15 <250.00
LDH (IU/L) total, (maximum) 499.27 (243.00–1022.00) 15 <250.00
LDH <250.00 IU/L, % (n) 26.7 (4) 15
LDH >250.00 IU/L, % (n) 93.3 (14) 15
Procalcitonin (ng/mL) 1.66 (0.10–15.28) 12 <0.25
D-dimer (mg/mL) 3.59 (0.29 to >20.00) 13 <0.80
D-dimer (mg/mL) (maximum) 5.52 (0.88 to >20.00) 13 <0.80
D-dimer >1.00 mg/mL, % (n) 69.2 (9) 13
D-dimer >5.00 mg/mL, % (n) 23.1 (3) 13
D-dimer >10.00 mg/mL, % (n) 23.1 (3) 13
Troponin above test-specific upper limit of normalb 26.7 (4) 15
Venous lactate (nmol/L) 1.76 (0.80–3.10) 10 <2.10
Hemolysate Markers
Hb (g/dL) 11.68 (6.40–15.10) 20 12.00–15.00
Hb <10.00 g/dL, % (n) 20.0 (4) 20
Haptoglobin (mg/dL) 213.15 (<30.00–475.20) 4 30.00–200.00
Haptoglobin <30.00mg/dL, % (n) 25.0 (1) 4
Haptoglobin >30.00mg/dL, % (n) 75.0 (3) 4
Total bilirubin (mg/dL) 2.61 (0.40–9.10) 15 <1.2
LDH (IU/L) total 381.73 (173.00–742.00) 15 <250.00
WBC: white blood cell count; ALC: absolute lymphocyte count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CPK: creatine phosphokinase; CRP:
c-reactive protein; LDH: lactate dehydrogenase; Hb: hemoglobin.
aMaximum indicates the highest laboratory values obtained during the patient’s hospitalization for that respective laboratory test.
bFor simplicity, we present the number and percentage of troponin test results that were above the upper limit of normal for any of the different troponin tests
currently in use, including troponin I, troponin T, and high-sensitivity troponin.
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which suggested that viral proteins ORF1ab, ORF10 and
ORF3a might cause the porphyrin-associated iron molecule
in heme, on the b1 chain of Hb, to dissociate. This would
affect the amount of oxygen that Hb could carry while in
the bloodstream. However, as sickle cell patients have a
mutation in the b chain of Hb, we wonder if this mutation
could potentially prevent the SARS-CoV-2 viral proteins
from binding, thus preventing the dissociation of iron. The
biochemical dynamics of the SARS-CoV-2 interaction with
sickle cell disease/sickle cell trait isoforms of heme would be
an extremely interesting avenue of research.
Another interesting observation was that only one sickle
cell disease patient in our study was diagnosed with VTE.
Multiple reports have shown that COVID-19 infection is
associated with high risk of VTE. Lodigiani et al. [11] found
that 21.0% of 388 consecutive COVID-19 patients (27.6%
ICU, 6.6% general ward) treated at a large hospital in Italy
developed thromboembolic complications. Sickle cell disease
itself is a well-described hypercoagulable state. A cross-sec-
tional analysis of 404 sickle cell disease patients at Johns
Hopkins University, Baltimore, MD, USA, showed that one
quarter of the patients had a history of VTE, and that sickle
cell variant genotypes conferred a higher risk of non catheter
related VTE relative to patients with sickle cell disease, which
the authors attributed to increased whole blood viscosity [12].
We hypothesized that the low number of VTE in our cohort
was possibly due to under-testing for VTE and also possibly
due to the overall number of patients with non severe, non
critical COVID-19 disease who did not require ICU care.
Currently there are no published guidelines for patients
with sickle cell disease/sickle cell trait in regard to the COVID-
19 pandemic, although the American Society of Hematology
provides guidance for frequently encountered questions by
health care providers [13]. Continued patient social distancing
measures, vigilance in recognizing COVID-19 symptoms by
providers, and preemptive management with hydration/pain
control will likely help mitigate the effect of COVID-19 on our
sickle cell patient population. Limitations of our study were its
retrospective nature, overall low number of the patients, and
the self-report of comorbidities on admission.
Conclusions
In this report, patients with sickle cell disease/sickle cell trait
and laboratory-confirmed COVID-19 had a generally mild,
or unremarkable, course of disease, with lower chances of
intubation, ICU admission and death, but with longer hospi-
tal stay. Further large-scale studies are needed to establish
the impact of COVID-19 on sickle cell disease/sickle cell
trait patients and the underlying mechanisms of disease in
this unique population.
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